Detailed contribution information
| Contribution title | Assessing post-marketing surveillance to identify the spectrum of cutaneous adverse events linked to checkpoint inhibitors |
|---|---|
| Authors | |
| Form of presentation | Poster |
| Topic |
|
| Contribution title | Assessing post-marketing surveillance to identify the spectrum of cutaneous adverse events linked to checkpoint inhibitors |
|---|---|
| Authors | |
| Form of presentation | Poster |
| Topic |
|